Next Generation Cancer Diagnostics Global Market Report 2025
상품코드:1889520
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
차세대 암 진단 시장 규모는 최근 급속도로 확대되고 있습니다. 2024년 127억 1,000만 달러에서 2025년에는 144억 달러로 성장하고, CAGR은 13.3%에 달할 전망입니다. 지난 수년간의 성장은 세계의 암 이환율 증가, 분자진단의 보급 확대, 조기 암 검출에 대한 수요 증가, 의료 인프라의 확충, 바이오마커에 기초한 스크리닝의 활용 확대에 의해 발생했습니다.
차세대 암 진단 시장 규모는 앞으로 수년간 빠른 성장이 예상됩니다. 2029년에는 234억 5,000만 달러에 달하고, CAGR은 13.0%를 나타낼 전망입니다. 예측기간 내 성장은 정밀종양학에 대한 주목의 고조, 저침습 진단 기술에 대한 수요 증가, 암 검출에서의 인공지능 및 디지털 툴의 도입 확대, 유전체 검사 서비스의 확충, 암 연구에 대한 정부 자금 증가에 의해 견인될 전망입니다. 예측 기간의 주요 동향으로는 비침습적 진단 분석 개발, 클라우드 기반 데이터 분석 통합, 나노기술 기반 바이오센서 혁신, 실세계 및 임상 데이터 수집, 로봇 공학 및 자동화 통합 등이 있습니다.
맞춤형 의료에 대한 수요 증가가 향후 수년간의 차세대 암 진단 시장의 확대를 견인할 것으로 예측됩니다. 맞춤형 의료는 각 환자에게 가장 효과적인 치료법을 확보하기 위해 개인의 유전자 구성, 생활 습관, 환경에 맞게 조정된 치료법입니다. 이 수요는 더 나은 임상 결과를 얻기 위해 표적화된 환자 고유의 치료가 필요한 만성 및 희귀질환의 유병률 증가에 의해 촉진되고 있습니다. 차세대 암 진단은 환자의 고유한 유전자 프로파일과 종양 프로파일에 기초한 맞춤형 치료 전략을 수립하기 위한 정밀한 분자 수준의 발견을 제공함으로써 맞춤형 의료를 지원합니다. 예를 들어 2024년 2월 미국 비영리 단체 '맞춤형 의료연합'이 보고한 바에 따르면 2023년 FDA가 희소질환 환자를 위한 신규 맞춤형 치료를 16건 승인하였으며 2022년 6건에서 현저한 증가를 보였습니다. 따라서 맞춤형 의료에 대한 수요 증가가 차세대 암 진단 시장의 성장을 견인하고 있습니다.
차세대 암 진단 시장의 주요 기업은 조기 발견, 맞춤형 치료, 임상 판단의 향상을 도모하기 위해 인공지능(AI) 멀티모달 진단 플랫폼 등의 혁신적인 솔루션을 개발하고 있습니다. 이러한 AI 멀티모달 플랫폼은 유전체 정보, 단백체 정보, 이미지 데이터, 임상 정보 등 다양한 생물학적 데이터를 통합 분석해 보다 정확하고 개별화된 암 검출 및 진단을 실현합니다. 예를 들어, 2025년 4월에는 인도에 거점을 둔 정밀 종양학 기업인 OneCell Diagnostics Pvt Ltd.가 정밀 종양학용으로 설계된 멀티모달 암 진단 플랫폼 'OncoIncytes'를 발표했습니다. 이 플랫폼은 순환 종양 DNA, 단일 세포 순환 종양 세포, RNA 데이터 및 150개 단백질의 상세한 프로파일을 단일 세포 수준에서 통합합니다. AI와 머신러닝을 활용한 1,080개 유전자 패널을 사용하는 OncoIncytes는 특히 초기 단계 연구 및 항체 약물 복합체(ADC) 개발에서 임상시험의 성과 향상으로 이어지는 고감도 및 고특이적 인사이트를 제공합니다. 본 플랫폼은 비침습적 실시간 확장 가능한 진단 기술을 통해 맞춤 암 검출, 치료 모니터링, 신약 개발을 지원합니다. 이러한 모든 기능은 CLIA 인증 실험실에서 OneCell의 독점적인 iDiscover 애플리케이션을 통해 사용할 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 차세대 암 진단 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 차세대 암 진단 시장 : 성장률 분석
세계의 차세대 암 진단 시장 실적 : 규모와 성장(2019-2024년)
세계의 차세대 암 진단 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 차세대 암 진단 시장 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 차세대 암 진단 시장 : 기술별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
차세대 시퀀싱(NGS)
Q 중합효소 연쇄반응 및 다중화
랩온어칩(LOAC) 및 역전사 중합효소 연쇄반응(RT-PCR)
순환 종양 DNA 분석
단백질 마이크로어레이
디옥시리보핵산 마이크로어레이
기타 멀티오믹스 플랫폼
세계의 차세대 암 진단 시장 : 암 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
폐암
유방암
대장암
자궁경부암
세계의 차세대 암 진단 시장 : 기능별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
치료 모니터링
동반 진단
예후 진단
암 검진
리스크 분석
세계의 차세대 암 진단 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
바이오마커 개발
순환 종양 세포(CTC) 분석
단백질체학 해석
후성 유전 분석
유전자 분석
세계의 차세대 암 진단 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원 및 진료소
진단실험실
연구기관 및 학술기관
제약 및 생명공학 기업
가정 치료 환경
세계의 차세대 암 진단 시장 세분화 : 차세대 시퀀싱, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
전장 유전체 시퀀싱
표적 유전자 시퀀싱
엑솜 시퀀싱
트랜스크립트 시퀀싱
세계의 차세대 암 진단 시장 세분화 : Q 중합효소 연쇄반응 및 다중화, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
정량 중합효소 연쇄반응
디지털 중합효소 연쇄반응
다중 중합효소 연쇄반응
역전사 중합효소 연쇄반응
세계의 차세대 암 진단 시장 세분화 : 랩온어칩 및 역전사 중합효소 연쇄반응, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
마이크로플루이딕스 칩 분석
통합형 역전사 중합효소 연쇄반응 칩
포인트 오브 케어 랩온어칩 디바이스
고처리량 랩온어칩 시스템
세계의 차세대 암 진단 시장 세분화 : 순환 종양 DNA 분석, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
단일 유전자 순환 종양 디옥시리보핵산 분석
다중 유전자 순환 종양 디옥시리보핵산 패널
디지털 드롭렛 순환 종양 DNA 검정
차세대 시퀀싱 순환 종양 DNA 분석
세계의 차세대 암 진단 시장 세분화 : 단백질 마이크로어레이, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
분석용 단백질 마이크로어레이
기능성 단백질 마이크로어레이
역상 단백질 마이크로어레이
항체 기반 단백질 마이크로어레이
세계의 차세대 암 진단 시장 세분화 : 디옥시리보핵산 마이크로어레이, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
유전자 발현 디옥시리보핵산 마이크로어레이
일염기 다형 제노타이핑 디옥시리보핵산 마이크로어레이
비교 유전체 하이브리드화 디옥시리보핵산 마이크로어레이
메틸화 디옥시리보핵산 마이크로어레이
세계의 차세대 암 진단 시장 세분화 : 기타 멀티오믹스 플랫폼, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
대사체학 플랫폼
에피유전체학 플랫폼
전사체학 플랫폼
통합 멀티오믹스 시스템
제7장 지역별 및 국가별 분석
세계의 차세대 암 진단 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 차세대 암 진단 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
차세대 암 진단 시장 : 경쟁 구도
차세대 암 진단 시장 : 기업 프로파일
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Abbott Laboratories Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Siemens Healthineers AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Danaher Corporation
Koninklijke Philips NV
General Electric Company
Becton, Dickinson and Company
Agilent Technologies Inc.
Illumina Inc.
Sysmex Corporation
Bio-Rad Laboratories Inc.
Exact Sciences Corporation
QIAGEN NV
Almac Group Ltd.
Natera Inc.
Myriad Genetics Inc.
NeoGenomics Inc.
Guardant Health Inc.
제32장 세계 시장의 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
차세대 암 진단 시장(2029년) : 새로운 기회를 제공하는 국가
차세대 암 진단 시장(2029년) : 새로운 기회를 제공하는 부문
차세대 암 진단 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Next generation cancer diagnostics refers to advanced diagnostic technologies that enable precise detection, characterization, and monitoring of cancer at the molecular and genetic levels. These diagnostics use cutting-edge tools such as genomics, proteomics, and liquid biopsy to support early detection, personalized treatment planning, and improved patient outcomes.
The main technologies used in next generation cancer diagnostics include next-generation sequencing (NGS), q-polymerase chain reaction and multiplexing, lab-on-a-chip (LOAC) and reverse transcriptase-polymerase chain reaction (RT-PCR), circulating tumor deoxyribonucleic acid (ctDNA) assays, protein microarrays, deoxyribonucleic acid microarrays, and others. Next-generation sequencing (NGS) is a high-throughput DNA sequencing method that enables rapid, simultaneous sequencing of millions of DNA fragments, allowing comprehensive analysis of genomes, transcriptomes, and genetic variations. These technologies target various cancer types, including lung cancer, breast cancer, colorectal cancer, and cervical cancer. Their functions include therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis. They are applied in biomarker development, circulating tumor cell (CTC) analysis, proteomic analysis, epigenetic analysis, and genetic analysis, and serve end users such as hospitals and clinics, diagnostic laboratories, research and academic institutions, pharmaceutical and biotechnology companies, and home care settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The next generation cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides next generation cancer diagnostics market statistics, including next generation cancer diagnostics industry global market size, regional shares, competitors with a next generation cancer diagnostics market share, detailed next generation cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next generation cancer diagnostics industry. This next generation cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The next generation cancer diagnostics market size has grown rapidly in recent years. It will grow from $12.71 billion in 2024 to $14.40 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period resulted from the increasing prevalence of cancer worldwide, growing adoption of molecular diagnostics, rising demand for early cancer detection, expansion of healthcare infrastructure, and greater use of biomarker-based screening.
The next generation cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $23.45 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period will be driven by a rising focus on precision oncology, increasing demand for minimally invasive diagnostic techniques, growing adoption of artificial intelligence and digital tools in cancer detection, expansion of genomic testing services, and increasing government funding for cancer research. Major trends in the forecast period include the development of non-invasive diagnostic assays, integration of cloud-based data analytics, innovations in nanotechnology-based biosensors, incorporation of real-world evidence and clinical data, and the integration of robotics and automation.
The rising demand for personalized medicines is expected to drive the expansion of the next-generation cancer diagnostics market in the coming years. Personalized medicines are treatments tailored to an individual's genetic makeup, lifestyle, and environment to ensure the most effective therapy for each patient. This demand is fueled by the growing prevalence of chronic and rare diseases, which require targeted, patient-specific treatments for better clinical outcomes. Next-generation cancer diagnostics support personalized medicine by providing precise molecular insights that inform customized treatment strategies based on a patient's unique genetic and tumor profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a notable increase from six approvals in 2022. Consequently, the rising demand for personalized medicines is driving the growth of the next-generation cancer diagnostics market.
Key players in the next-generation cancer diagnostics market are developing innovative solutions such as artificial intelligence-driven multi-modal diagnostic platforms to improve early detection, personalized therapy, and clinical decision-making. These AI-powered multi-modal platforms integrate and analyze diverse biological data-including genomic, proteomic, imaging, and clinical information-to deliver more accurate and individualized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform designed for precision oncology. The platform combines circulating tumor DNA, single-cell circulating tumor cells, RNA data, and detailed protein profiles of 150 proteins at the single-cell level. Using a 1,080-gene panel powered by AI and machine learning, OncoIncytes provides highly sensitive and specific insights to improve clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform facilitates personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell's proprietary iDiscover application from a CLIA-certified laboratory.
In June 2023, Quest Diagnostics Inc., a US-based healthcare diagnostics company, acquired Haystack Oncology for an undisclosed amount. This acquisition aimed to strengthen Quest Diagnostics' capabilities in the rapidly growing minimal residual disease (MRD) liquid biopsy market. Haystack Oncology Inc., a US-based firm, provides next-generation cancer diagnostics through its tumor-informed MRD test, Haystack MRD.
Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.
North America was the largest region in the next generation cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next generation cancer diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the next generation cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The next generation cancer diagnostics market consists of revenues earned by entities by providing services such as genomic and molecular profiling, liquid biopsy testing, next-generation sequencing (NGS) services, companion diagnostics development, and bioinformatics and data interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next generation cancer diagnostics market also includes sales of gene panels, single-cell analysis systems, nanotechnology-based biosensors, molecular imaging agents, and exosome isolation kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Next Generation Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on next generation cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for next generation cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next generation cancer diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Technology: Next-Generation Sequencing (NGS); QPolymerase Chain Reaction And Multiplexing; Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR); Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays; Protein Microarrays; Deoxyribonucleic Acid Microarrays; Other Multi-Omics Platforms
2) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Cervical Cancer
3) By Function: Therapeutic Monitoring; Companion Diagnostics; Prognostics; Cancer Screening; Risk Analysis
5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Pharmaceutical And Biotechnology Companies; Home Care Settings
5) By Protein Microarrays: Analytical Protein Microarrays; Functional Protein Microarrays; Reverse Phase Protein Microarrays; Antibody-Based Protein Microarrays
2. Next Generation Cancer Diagnostics Market Characteristics
3. Next Generation Cancer Diagnostics Market Trends And Strategies
4. Next Generation Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Next Generation Cancer Diagnostics Growth Analysis And Strategic Analysis Framework
5.1. Global Next Generation Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Next Generation Cancer Diagnostics Market Growth Rate Analysis
5.4. Global Next Generation Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Next Generation Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Next Generation Cancer Diagnostics Total Addressable Market (TAM)
6. Next Generation Cancer Diagnostics Market Segmentation
6.1. Global Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Next-Generation Sequencing (NGS)
QPolymerase Chain Reaction And Multiplexing
Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
6.2. Global Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
6.3. Global Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
6.4. Global Next Generation Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biomarker Development
Circulating Tumor Cell (CTC) Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
6.5. Global Next Generation Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Diagnostic Laboratories
Research And Academic Institutions
Pharmaceutical And Biotechnology Companies
Home Care Settings
6.6. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Next-Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Whole Genome Sequencing
Targeted Gene Sequencing
Exome Sequencing
Transcriptome Sequencing
6.7. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Quantitative Polymerase Chain Reaction And Multiplexing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Quantitative Polymerase Chain Reaction
Digital Polymerase Chain Reaction
Multiplex Polymerase Chain Reaction
Reverse Transcription Polymerase Chain Reaction
6.8. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.9. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Circulating Tumor Deoxyribonucleic Acid Assays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.10. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Protein Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Analytical Protein Microarrays
Functional Protein Microarrays
Reverse Phase Protein Microarrays
Antibody-Based Protein Microarrays
6.11. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Deoxyribonucleic Acid Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gene Expression Deoxyribonucleic Acid Microarrays
Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays
6.12. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Other Multi-Omics Platforms, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metabolomics Platforms
Epigenomics Platforms
Transcriptomics Platforms
Integrated Multi-Omics Systems
7. Next Generation Cancer Diagnostics Market Regional And Country Analysis
7.1. Global Next Generation Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Next Generation Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Next Generation Cancer Diagnostics Market
8.1. Asia-Pacific Next Generation Cancer Diagnostics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Next Generation Cancer Diagnostics Market
9.1. China Next Generation Cancer Diagnostics Market Overview
9.2. China Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Next Generation Cancer Diagnostics Market
10.1. India Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Next Generation Cancer Diagnostics Market
11.1. Japan Next Generation Cancer Diagnostics Market Overview
11.2. Japan Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Next Generation Cancer Diagnostics Market
12.1. Australia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Next Generation Cancer Diagnostics Market
13.1. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Next Generation Cancer Diagnostics Market
14.1. South Korea Next Generation Cancer Diagnostics Market Overview
14.2. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Next Generation Cancer Diagnostics Market
15.1. Western Europe Next Generation Cancer Diagnostics Market Overview
15.2. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Next Generation Cancer Diagnostics Market
16.1. UK Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Next Generation Cancer Diagnostics Market
17.1. Germany Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Next Generation Cancer Diagnostics Market
18.1. France Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Next Generation Cancer Diagnostics Market
19.1. Italy Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Next Generation Cancer Diagnostics Market
20.1. Spain Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Next Generation Cancer Diagnostics Market
21.1. Eastern Europe Next Generation Cancer Diagnostics Market Overview
21.2. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Next Generation Cancer Diagnostics Market
22.1. Russia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Next Generation Cancer Diagnostics Market
23.1. North America Next Generation Cancer Diagnostics Market Overview
23.2. North America Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Next Generation Cancer Diagnostics Market
24.1. USA Next Generation Cancer Diagnostics Market Overview
24.2. USA Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Next Generation Cancer Diagnostics Market
25.1. Canada Next Generation Cancer Diagnostics Market Overview
25.2. Canada Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Next Generation Cancer Diagnostics Market
26.1. South America Next Generation Cancer Diagnostics Market Overview
26.2. South America Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Next Generation Cancer Diagnostics Market
27.1. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Next Generation Cancer Diagnostics Market
28.1. Middle East Next Generation Cancer Diagnostics Market Overview
28.2. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Next Generation Cancer Diagnostics Market
29.1. Africa Next Generation Cancer Diagnostics Market Overview
29.2. Africa Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Next Generation Cancer Diagnostics Market Competitive Landscape And Company Profiles
30.1. Next Generation Cancer Diagnostics Market Competitive Landscape
30.2. Next Generation Cancer Diagnostics Market Company Profiles
30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
31. Next Generation Cancer Diagnostics Market Other Major And Innovative Companies
31.1. Danaher Corporation
31.2. Koninklijke Philips N.V.
31.3. General Electric Company
31.4. Becton, Dickinson and Company
31.5. Agilent Technologies Inc.
31.6. Illumina Inc.
31.7. Sysmex Corporation
31.8. Bio-Rad Laboratories Inc.
31.9. Exact Sciences Corporation
31.10. QIAGEN N.V.
31.11. Almac Group Ltd.
31.12. Natera Inc.
31.13. Myriad Genetics Inc.
31.14. NeoGenomics Inc.
31.15. Guardant Health Inc.
32. Global Next Generation Cancer Diagnostics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Next Generation Cancer Diagnostics Market
34. Recent Developments In The Next Generation Cancer Diagnostics Market
35. Next Generation Cancer Diagnostics Market High Potential Countries, Segments and Strategies
35.1 Next Generation Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
35.2 Next Generation Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
35.3 Next Generation Cancer Diagnostics Market In 2029 - Growth Strategies
